Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo, Sara Bringhen, Heinz Ludwig, Meletios A. Dimopoulos, Joan Bladé, Maria V. Mateos, Laura Rosiñol, Mario Boccadoro, Michele Cavo, Henk Lokhorst, Sonja Zweegman, Evangelos Terpos, Faith Davies, Christoph Driessen, Peter Gimsing, Martin Gramatzki, Roman Hàjek, Hans E. Johnsen, Fernando Leal Da Costa, Orhan Sezer, Andrew Spencer, Meral Beksac, Gareth Morgan, Hermann Einsele, Jesus F. San Miguel, and Pieter Sonneveld Blood Volume 118(17):4519-4529 October 27, 2011 ©2011 by American Society of Hematology

Five-year relative survival rates according to the year of diagnosis and the patients' age at diagnosis. Five-year relative survival rates according to the year of diagnosis and the patients' age at diagnosis. Survival rates have increased over the past 35 years in all patient age groups, a trend attributed to the effect of novel agents such as thalidomide, bortezomib, and lenalidomide; however, significant increases in survival have only been observed in patients aged < 65 years at initial diagnosis.3 Antonio Palumbo et al. Blood 2011;118:4519-4529 ©2011 by American Society of Hematology

The interrelation between the 3 components of vulnerability (comorbidity, frailty, and disability) and the main health care implications associated with each factor. The interrelation between the 3 components of vulnerability (comorbidity, frailty, and disability) and the main health care implications associated with each factor. Antonio Palumbo et al. Blood 2011;118:4519-4529 ©2011 by American Society of Hematology

Treatment algorithm for elderly frail patients (adapted from Palumbo and Anderson46). Antonio Palumbo et al. Blood 2011;118:4519-4529 ©2011 by American Society of Hematology